P. Carpentier

Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer

Cora N. Sternberg, Herlinde Dumez, Hendrik Van Poppel et al. · Annals of Oncology · 2009 · 123 citations

Medicine, Oncology, Pharmacology +15

Intravesical BCG in Patients with Carcinoma in situ of the Urinary Bladder: Long–Term Results of EORTC GU Group Phase II Protocol 30861

G. Jakse, R. Hall, Aldo Bono et al. · European Urology · 2001 · 98 citations

Medicine, Oncology, Urology +5

Transrectal Ultrasonography in the Followup of Prostatic Carcinoma Patients

P. Carpentier, Fritz H. Schroeder, J. Blom · The Journal of Urology · 1982 · 45 citations

Medicine, Radiology, Urology +14

Transrectal Ultrasonography in the Followup of Prostatic Carcinoma Patients: A New Prognostic Parameter?

P. Carpentier, Fritz H. Schröder · The Journal of Urology · 1984 · 43 citations

Medicine, Oncology, Urology +17

A European Organization for Research and Treatment of Cancer—Genitourinary Group Phase 2 Study of Chemotherapy in Stage T3-4N0-XM0 Transitional Cell Cancer of the Bladder: Evaluation of Clinical Response

Ted A.W. Splinter, M. Pavone‐Macaluso, Didier Jacqmin et al. · The Journal of Urology · 1992 · 42 citations

Medicine, Oncology, Surgery +16